

December 27, 2018

Via E-mail: [AGO.highcostprescriptiondrugs@vermont.gov](mailto:AGO.highcostprescriptiondrugs@vermont.gov)

Re: Notice of New Drug Introduction Pursuant to 18 V.S.A. s. 4637

Dear Ms. Abrams:

Teva Pharmaceuticals USA, Inc. ("Teva") submits this information pursuant to 18 V.S.A. s. 4637(b).


Teva has released the following generic prescription drug to the commercial market on or about December 27, 2018:

NDC	Product Description	WAC
00591-2944-87	PIMECROLIMUS 1% CREAM 100GM	\$812.51

Teva reserves any and all rights that it may have to challenge the governing statute, its interpretation, or the application of it to Teva.

Thank you for your consideration.

Sincerely,



Jason B. Daly  
VP & General Counsel - NA Commercial & Generics  
Teva Pharmaceuticals USA, Inc.